Learn about CVE-2017-18228, a Cross-Site Scripting (XSS) vulnerability in BMC Remedy AR System 9.1. Find out the impact, affected systems, exploitation mechanism, and mitigation steps.
BMC Remedy AR System 9.1 is susceptible to a Cross-Site Scripting (XSS) vulnerability through the ATTKey parameter in an arsys/servlet/AttachServlet request.
Understanding CVE-2017-18228
This CVE entry describes a security issue in BMC Remedy AR System 9.1 that could potentially allow an attacker to execute XSS attacks.
What is CVE-2017-18228?
The ATTKey parameter in the arsys/servlet/AttachServlet request in BMC Remedy AR System 9.1 can be manipulated by an attacker to inject malicious scripts, leading to XSS vulnerabilities.
The Impact of CVE-2017-18228
Exploitation of this vulnerability could result in unauthorized access to sensitive data, session hijacking, and potential compromise of user information.
Technical Details of CVE-2017-18228
This section provides more in-depth technical information about the vulnerability.
Vulnerability Description
The vulnerability exists in Remedy Mid Tier in BMC Remedy AR System 9.1, allowing attackers to conduct XSS attacks via the ATTKey parameter in the arsys/servlet/AttachServlet request.
Affected Systems and Versions
Exploitation Mechanism
Attackers can exploit the vulnerability by injecting malicious scripts through the ATTKey parameter in specific requests, potentially leading to XSS attacks.
Mitigation and Prevention
Protecting systems from CVE-2017-18228 requires immediate actions and long-term security practices.
Immediate Steps to Take
Long-Term Security Practices
Patching and Updates
Regularly update and patch BMC Remedy AR System 9.1 to ensure that known vulnerabilities, including CVE-2017-18228, are mitigated effectively.